Cytochrome-c Oxidase Deficiency
|
0.640 |
Biomarker
|
disease |
BEFREE |
Our analyses define COA6 as a constituent of the mitochondrial copper relay system, linking defects in COX2 metallation to cardiac cytochrome c oxidase deficiency.
|
25959673 |
2015 |
Cytochrome-c Oxidase Deficiency
|
0.640 |
Biomarker
|
disease |
BEFREE |
The accumulation of H(2)S over time causes progressive COX deficiency in animal tissues and human cells, which is associated with reduced amount of COX holoenzyme, and of several COX subunits, including mitochondrially encoded cytochrome c oxidase 1 (MTCO1), MTCO2, COX4, and COX5A.
|
20812865 |
2011 |
Cytochrome-c Oxidase Deficiency
|
0.640 |
GeneticVariation
|
disease |
BEFREE |
Despite mitochondrial proliferation and transcriptional upregulation of nuclear and mtDNA-encoded COX genes (including MT-CO2), a severe COX deficiency was found with all investigations of the muscle biopsy (histochemistry, biochemistry, immunoblotting).
|
18245391 |
2008 |
Cytochrome-c Oxidase Deficiency
|
0.640 |
GermlineCausalMutation
|
disease |
ORPHANET |
Severe lactic acidosis caused by a novel frame-shift mutation in mitochondrial-encoded cytochrome c oxidase subunit II.
|
11471180 |
2001 |
Cytochrome-c Oxidase Deficiency
|
0.640 |
GermlineCausalMutation
|
disease |
ORPHANET |
Cytochrome c oxidase deficiency.
|
11579424 |
2001 |
Cytochrome-c Oxidase Deficiency
|
0.640 |
GermlineCausalMutation
|
disease |
ORPHANET |
Early-onset multisystem mitochondrial disorder caused by a nonsense mutation in the mitochondrial DNA cytochrome C oxidase II gene.
|
11558799 |
2001 |
Cytochrome-c Oxidase Deficiency
|
0.640 |
GermlineCausalMutation
|
disease |
ORPHANET |
An mtDNA mutation in the initiation codon of the cytochrome C oxidase subunit II gene results in lower levels of the protein and a mitochondrial encephalomyopathy.
|
10205264 |
1999 |
Cytochrome-c Oxidase Deficiency
|
0.640 |
GeneticVariation
|
disease |
BEFREE |
In the following article, the phenotypes of the two Ptgs (genes coding for COX-1 and COX-2) knockouts are summarized, and recent studies to investigate the effects of COX deficiency on cancer susceptibility, inflammatory response, gastric ulceration, and female reproductive processes are discussed.
|
10487525 |
1999 |
Cytochrome-c Oxidase Deficiency
|
0.640 |
GeneticVariation
|
disease |
UNIPROT |
A missense mutation of cytochrome oxidase subunit II causes defective assembly and myopathy.
|
10486321 |
1999 |
Cytochrome-c Oxidase Deficiency
|
0.640 |
GermlineCausalMutation
|
disease |
ORPHANET |
A missense mutation of cytochrome oxidase subunit II causes defective assembly and myopathy.
|
10486321 |
1999 |
Cytochrome-c Oxidase Deficiency
|
0.640 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
MELAS Syndrome
|
0.520 |
GermlineCausalMutation
|
disease |
ORPHANET |
Isolated cytochrome c oxidase deficiency as a cause of MELAS.
|
18245391 |
2008 |
MELAS Syndrome
|
0.520 |
GeneticVariation
|
disease |
BEFREE |
High prevalence of the COII/tRNA(Lys) intergenic 9-bp deletion in mitochondrial DNA of Taiwanese patients with MELAS or MERRF syndrome.
|
15965049 |
2005 |
MELAS Syndrome
|
0.520 |
Biomarker
|
disease |
BEFREE |
The pattern of expression of genes for mtDNA-encoded ribosomal RNA and the protein-coding region cytochrome c oxidase subunit II were similar in muscle specimens of patients with MELAS, patients with chronic progressive external ophthalmoplegia, and normal control subjects, and also between the two MELAS mutations.
|
7684581 |
1993 |
MELAS Syndrome
|
0.520 |
Biomarker
|
disease |
CTD_human |
|
|
|
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Combining clinical factors and COX-2/C-MET/KRAS expression status, our models provided accurate prognostic information in CRC.
|
30720004 |
2020 |
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
This study sought to evaluate short-term treatment with COX-2 inhibitors and acute changes in colonic PGE2 levels as predictors of long-term efficacy in a genetic model of colorectal cancer.
|
31797003 |
2020 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Inhibition of COX-2 and 5-LOX regulates the progression of colorectal cancer by promoting PTEN and suppressing PI3K/AKT pathway.
|
29339153 |
2019 |
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Prognostic significance of EGFR and COX-2 expression in colorectal cancer and their association. A study in Greek population.
|
29552755 |
2019 |
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
COX-2 expression was positive in 40/49 CRCs, bearing cytoplasmic and heterogeneous staining, from moderate to high intensity.
|
31614548 |
2019 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The CRC protective effects of apiaceous vegetables are mainly due to the inhibitory effect of FaOH and FaDOH on NF-κB and its downstream inflammatory markers, especially COX-2.
|
31540047 |
2019 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therefore, the present study was designed to assess the prophylactic potentials of probiotics (Lactobacillus acidophilus and Lactobacillus rhamnosus GG) in conjunction with celecoxib, a selective cox-2 inhibitor in 1,2 dimethylhydrazine dihydrochloride (DMH)-induced experimental colon carcinogenesis, a well-established, well appreciated and widely used model for colorectal cancer that shares many similarities to human sporadic colorectal cancer with respect to response to some promotional and preventive agents.
|
30183370 |
2019 |
Colorectal Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In the COS-treated CRC group (CMCOS), COS protected mice from CRC by decreasing the disease activity index, tumor incidences and multiplicity, and the mRNA levels of COX-2, IL-6, TNF-α, IL-1β, IL-10, and IKK-β mRNA in colonic epithelial cells.
|
31620100 |
2019 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The CRC condition was produced in response to COX-2 and IL-6 induced activation of JAK2/STAT3 which, in turn, was due to the enhanced phosphorylation of JAK2 and STAT3.
|
29580751 |
2019 |
Colorectal Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
c-Myb and its Effector COX-2 as an Indicator Associated with Prognosis and Therapeutic Outcome in Colorectal Cancer.
|
31205515 |
2019 |